A promising daily tablet is effective at increasing height and improving proportional limb growth in children with achondroplasia, the most common form of dwarfism, according to a new study.

At the core of achondroplasia's pathology lies the hyperactivation of FGFR3, which impairs not only the growth of long bones but also affects cranial, spinal, and vertebral development.

The double-blind placebo-controlled ApproaCH Trial included 84 children with achondroplasia (aged 2-11 years) randomized 2:1 (TransCon CNP:placebo) for 52 weeks, followed by an open-label ...

Discover top medications for 'treating Achondroplasia'? This page compiles essential information on generic and brand-name drugs specifically used for Achondroplasia treatment.Here, you can ...

Assessments were performed with the SF-10 and Achondroplasia Child Experience Measure (ACEM), with statistically significant improved outcome in TransCon CNP treated versus placebo for ...